Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$105,000.00

Dissecting Mechanisms of Echinocandin Tolerance and Resistance in the Fungal Pathogen Candida albicans

EF 2012-13

Résumé
Candida albicans is the leading cause of fungal infection in humans, and is capable of causing lethal bloodstream infections in immunocompromised individuals, including patients with HIV and those undergoing chemotherapy. There are a very limited number of antifungal drug classes available for treatment of these infections that do not have toxic side effects to the patient. The echinocandins are the only new class of antifungals to reach the clinic in decades, and function by causing loss of fungal cell wall integrity, thus killing the cell. C. albicans has developed resistance to these drugs and therefore there is a pressing need for new strategies to block resistance and improve the efficacy of the few antifungals available. The main mechanism of resistance to the echinocandins is mutations in the drug target; however, additional mechanisms remain to be determined. The goal of my project is to identify new mechanisms of echinocandin resistance, and to develop therapeutic strategies to reduce this resistance. As a pilot, I have screened a library of C. albicans gene deletion mutants to look for genes that are involved in the response to the echinocandins. I propose to perform this screen on a large scale, using a larger gene deletion library, and to delete the relevant genes in an echinocandin-resistant strain of C. albicans to see if resistance is reduced. In order to develop new therapeutic strategies to reduce this resistance, I have initially screened a library of drug compounds for those that are able to improve the efficacy of the echinocandins against a resistant strain of C. albicans. I have identified 19 such compounds, and propose to screen further drug libraries. Future investigations will involve testing toxicity to mammalian cells, and determining the modes of action of these compounds. My project is poised to identify new mechanisms involved in echinocandin resistance and has broad therapeutic potential.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
283891
Name
Polvi Elizabeth
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Dissecting Mechanisms of Echinocandin Tolerance and Resistance in the Fungal Pathogen Candida albicans
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antifungals; Candida Albicans; Drug Resistance; Drug Tolerance; Echinocandins; Fungal Pathogens; Gene Expression; Genomics; Haploinsufficiency Profiling; Heat Shock Protein 90 (Hsp90)
Abstract
Candida albicans is the leading cause of fungal infection in humans, and is capable of causing lethal bloodstream infections in immunocompromised individuals, including patients with HIV and those undergoing chemotherapy. There are a very limited number of antifungal drug classes available for treatment of these infections that do not have toxic side effects to the patient. The echinocandins are the only new class of antifungals to reach the clinic in decades, and function by causing loss of fungal cell wall integrity, thus killing the cell. C. albicans has developed resistance to these drugs and therefore there is a pressing need for new strategies to block resistance and improve the efficacy of the few antifungals available. The main mechanism of resistance to the echinocandins is mutations in the drug target; however, additional mechanisms remain to be determined. The goal of my project is to identify new mechanisms of echinocandin resistance, and to develop therapeutic strategies to reduce this resistance. As a pilot, I have screened a library of C. albicans gene deletion mutants to look for genes that are involved in the response to the echinocandins. I propose to perform this screen on a large scale, using a larger gene deletion library, and to delete the relevant genes in an echinocandin-resistant strain of C. albicans to see if resistance is reduced. In order to develop new therapeutic strategies to reduce this resistance, I have initially screened a library of drug compounds for those that are able to improve the efficacy of the echinocandins against a resistant strain of C. albicans. I have identified 19 such compounds, and propose to screen further drug libraries. Future investigations will involve testing toxicity to mammalian cells, and determining the modes of action of these compounds. My project is poised to identify new mechanisms involved in echinocandin resistance and has broad therapeutic potential.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Polvi, Elizabeth
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~